APAleksandra Palka

Aleksandra Palka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Palka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CURRENT THERAPEUTIC STRATEGIES IN PEDIATRIC PFAPA SYNDROME: EFFICACY, SAFETY, AND QUALITY-OF-LIFE CONSIDERATIONS – A NARRATIVE REVIEW

    by Monika Kamela, Adrianna Baran, Olaf Krawczyk, Katarzyna Boszczyk, Norbert Krawczyk, Aleksandra Palka, Natalia Krzysztofek, Wojciech Kopyciński, Małgorzata Grzybowska, Piotr Wilczkowski

    Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is a common periodic fever disorder of childhood. Although it usually has a favorable long-term course, recurrent attacks may substantially disrupt school attendance, family life, and quality of life. This narrative review summarizes current therapeutic strategies for pediatric PFAPA, focusing on efficacy, safety, and patient-centered outcomes. A structured PubMed/MEDLINE search, supplemented by the Cochrane Library and reference screening, was used to identify relevant evidence on corticosteroids, colchicine, cimetidine, non-standard preventive therapies, interleukin-1 inhibition, and tonsil surgery. Corticosteroids are highly effective for rapid termination of acute attacks but do not prevent recurrence and may shorten attack-free intervals in some patients. Colchicine has the strongest evidence among pharmacological preventive options and can reduce attack frequency and corticosteroid use. Evidence for cimetidine, ketotifen, probiotics, and vitamin D is more limited. Tonsillectomy may lead to sustained remission and can improve quality of life and school functioning, but spontaneous remission, surgical risk, incomplete response, and recurrence must be considered. Evidence for interleukin-1 inhibition remains insufficient for routine use. Current data do not support one universally superior treatment. Management should be individualized according to attack burden, response to previous therapy, safety, quality of life, and family preferences. Better prospective comparative studies with standardized outcomes are needed.

  • Open Access

    ARTIFICIAL INTELLIGENCE IN PSYCHIATRIC DIAGNOSIS AND CLINICAL DECISION-MAKING: CURRENT EVIDENCE, CLINICAL APPLICATIONS, CHALLENGES AND FUTURE DIRECTIONS

    by Aleksandra Palka, Wojciech Kopyciński, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Katarzyna Boszczyk, Małgorzata Grzybowska, Adrianna Baran, Olaf Krawczyk

    Artificial intelligence (AI) is increasingly investigated as a means of supporting psychiatric diagnosis and clinical decision-making. This narrative review critically evaluates its current clinical applications, limitations, ethical challenges, and readiness for implementation in psychiatric practice. A literature search of PubMed, Scopus, Web of Science, and Google Scholar was conducted for English-language publications issued between January 2020 and July 2026, supplemented by earlier landmark contributions. Following duplicate removal and eligibility screening, 111 publications were included in a clinically oriented narrative synthesis. Machine learning, deep learning, natural language processing, digital biomarkers, and large language models have demonstrated potential applications in diagnostic classification, symptom monitoring, treatment-response prediction, relapse and suicide-risk assessment, clinical documentation, and precision psychiatry. Promising performance in retrospective or internally validated datasets has not yet been matched by robust evidence of improved clinical decisions or patient outcomes. Major limitations include small and unrepresentative samples, methodological heterogeneity, insufficient external and prospective validation, inadequate calibration, limited interpretability, inconsistent safety assessment, and vulnerability to bias and automation-related errors. These concerns are particularly important in high-risk applications involving suicide prediction, treatment allocation, and direct patient interaction. AI should augment rather than replace comprehensive clinical assessment and professional judgment. Translation into routine practice will require prospective multicenter studies, representative longitudinal datasets, transparent reporting, subgroup-specific fairness evaluation, meaningful human oversight, stakeholder co-design, and continuous post-deployment monitoring. The value of psychiatric AI should ultimately be determined by whether it safely and equitably improves clinical decisions and patient-relevant outcomes.

  • Open Access

    SLEEP DISTURBANCES AND FATIGUE IN ANKYLOSING SPONDYLITIS: A NARRATIVE REVIEW OF PREVALENCE, MECHANISMS, CLINICAL IMPACT AND MANAGEMENT

    by Katarzyna Boszczyk, Olaf Krawczyk, Wojciech Kopyciński, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Małgorzata Grzybowska, Adrianna Baran, Aleksandra Palka

    Sleep disturbances and fatigue are common and burdensome manifestations of ankylosing spondylitis (AS). They are strongly associated with overall disease burden and impaired health-related quality of life. This narrative review summarises current evidence on their prevalence, underlying mechanisms, clinical consequences, assessment and management. Sleep disturbances affect approximately half of patients with AS, while clinically significant fatigue is reported by a similar proportion of patients across axSpA populations. Both symptoms are associated with greater pain, higher disease activity, impaired physical function, psychological distress, reduced social participation, and poorer quality of life. Fatigue may also affect selected dimensions of occupational functioning. Their pathogenesis is multifactorial. Inflammatory signalling may contribute to both symptoms, with TNF-α having the clearest established role in sleep regulation and broader inflammatory pathways, including TNF-α and IL-17, potentially contributing to fatigue. Pain, restricted mobility, functional impairment, anxiety, depression, chronic insomnia, and coexisting sleep disorders may also play important roles. Anti-inflammatory treatment can improve fatigue and patient-reported sleep outcomes, although objective sleep findings remain inconsistent and residual symptoms may persist despite improvements in disease activity. Exercise, physiotherapy, patient education, and appropriate management of insomnia and coexisting sleep disorders may complement pharmacological treatment. Sleep quality and fatigue should therefore be assessed directly as distinct patient-reported domains. Further longitudinal and interventional studies using standardised outcome measures are needed to clarify causal relationships, determine symptom-specific treatment effects, and support more individualised management.

  • Open Access

    BRUGADA SYNDROME: FROM DIAGNOSIS TO TREATMENT AND PREVENTION – CURRENT KNOWLEDGE

    by Norbert Krawczyk, Natalia Krzysztofek, Olaf Krawczyk, Monika Kamela, Piotr Wilczkowski, Aleksandra Palka, Małgorzata Grzybowska, Wojciech Kopyciński, Katarzyna Boszczyk, Adrianna Baran

    Brugada syndrome is a rare inherited cardiac arrhythmia disorder characterized by a high risk of sudden cardiac death in structurally normal hearts. This channelopathy is associated with syncope caused by ventricular tachyarrhythmias, especially among the male population. Current studies results show that this illness is not solely inherited in an autosomal dominant manner, which occurs in only 3 out of 10 patients. Intensive research has deepened the understanding of its genetic, electrophysiological and clinical aspects. However, Brugada syndrome remains a major diagnostic and therapeutic challenge, especially in asymptomatic patients and in risk stratification. The main type of treatment remains implantable cardioverter-defibrillator, but results of clinical studies show that epicardial ablation can also represent satisfactory results. This review provides a summarized synthesis of current knowledge on Brugada syndrome, including epidemiology, pathophysiology, genetic basis, clinical presentation, electrocardiographic characteristics and diagnostic criteria, risk stratification, treatment approaches and preventive measures in a comprehensive and detailed way.

  • Open Access

    THYROID STORM: FROM ENDOCRINE CRISIS TO CARDIOVASCULAR COLLAPSE — PATHOPHYSIOLOGY, DIAGNOSIS AND CONTEMPORARY MANAGEMENT

    by Małgorzata Grzybowska, Piotr Wilczkowski, Aleksandra Palka, Natalia Krzysztofek, Wojciech Kopyciński, Katarzyna Boszczyk, Norbert Krawczyk, Monika Kamela, Adrianna Baran, Olaf Krawczyk

    Thyroid storm is a rare but life-threatening endocrine emergency characterized by thyrotoxicosis accompanied by systemic decompensation and end-organ dysfunction. Despite advances in diagnosis and treatment, it remains associated with substantial mortality, cardiovascular failure and multiorgan dysfunction representing major causes of death. This narrative review aims to summarize current knowledge regarding the pathophysiology, clinical presentation, diagnostic approaches, cardiovascular complications, and contemporary treatment strategies for thyroid storm, with particular emphasis on the management of severe cardiovascular manifestations. A narrative literature review was conducted using PubMed and Google Scholar. Recent peer-reviewed studies, systematic reviews, case series, clinical guidelines, and international consensus recommendations were analyzed to provide an up-to-date overview of thyroid storm management. Thyroid storm requires rapid recognition based on clinical manifestations of systemic decompensation in the setting of biochemical thyrotoxicosis. Cardiovascular complications, including tachyarrhythmias, atrial fibrillation, acute heart failure, thyrotoxic cardiomyopathy, myocardial injury, cardiogenic shock, and cardiac arrest, are among the most clinically significant complications. Treatment requires a multimodal approach - antithyroid drugs, iodine, glucocorticoids, β-blockers, and supportive intensive care. Propranolol remains an important therapeutic option; however, β-blockade must be individualized in patients with impaired cardiac function or hemodynamic instability. Alternative and rescue therapies, including lithium, cholestyramine, therapeutic plasma exchange, and thyroidectomy, may be considered in refractory cases. Successful management of thyroid storm requires early diagnosis, prompt treatment, continuous cardiovascular monitoring, and an individualized multidisciplinary approach. Further studies are needed to establish optimal treatment strategies, particularly for patients with cardiovascular complications and those who fail or cannot tolerate conventional therapy.

  • Open Access

    FRONTOTEMPORAL DEMENTIA - COMPREHENSIVE INSIGHTS INTO PATHOGENESIS, DIAGNOSIS, AND INNOVATIVE TREATMENTS

    by Piotr Wilczkowski, Aleksandra Palka, Natalia Krzysztofek, Wojciech Kopyciński, Małgorzata Grzybowska, Katarzyna Boszczyk, Norbert Krawczyk, Monika Kamela, Adrianna Baran, Olaf Krawczyk

    Frontotemporal dementia (FTD) is a clinically and genetically diverse group of neurodegenerative disorders predominantly affecting the frontal and anterior temporal lobes, leading to progressive changes in behavior, language, and executive function. FTD is the most common cause of young-onset dementia and third overall among degenerative dementias, with a prevalence of 15–22 per 100,000 and an incidence of 2.7–4.1 per 100,000. The core clinical syndromes include the behavioral variant (bvFTD), semantic and nonfluent primary progressive aphasias (svPPA, nfvPPA), and overlap with motor disorders such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Genetic mutations, especially C9orf72, GRN, and MAPT, are responsible for most familial cases and involve proteinopathies with TDP-43, tau, and FUS proteins. Biomarkers (e.g., neurofilament light chain, progranulin) and neuroimaging are used to improve detection and differentiate subtypes, although reliable biomarkers are lacking. Management is largely supportive, with a combination of non-pharmacological therapies (e.g., exercise, speech and occupational strategies, behavioral tactics, caregiver education) and pharmacotherapy for neuropsychiatric symptoms. Clinical trials explore gene therapies and disease-modifying drugs, indicating a move towards personalized medicine. Despite major advances, obstacles persist for early detection and effective therapies, underlining the need for sustained multidisciplinary research in FTD.

  • Open Access

    MPOX: CURRENT CHALLENGES IN DIAGNOSIS, TREATMENT, PREVENTION, AND PUBLIC HEALTH – A NARRATIVE REVIEW

    by Wojciech Kopyciński, Olaf Krawczyk, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Katarzyna Boszczyk, Małgorzata Grzybowska, Adrianna Baran, Aleksandra Palka

    Mpox (monkeypox) has emerged as a major global public health concern following the unprecedented multinational outbreaks that began in 2022. Although historically considered a neglected zoonotic disease confined mainly to endemic regions of Central and West Africa, recent epidemiological changes, international spread, and the emergence of new viral clades have highlighted significant gaps in preparedness, surveillance, and access to medical countermeasures. The clinical spectrum of mpox has also evolved, with atypical presentations increasingly reported during recent outbreaks, creating additional diagnostic challenges for clinicians. This narrative review summarizes current evidence regarding the epidemiology, transmission, pathogenesis, clinical manifestations, diagnosis, treatment, prevention, and public health implications of mpox. Particular attention is given to limitations of existing diagnostic methods, the evolving evidence surrounding antiviral therapy, challenges associated with vaccine availability and effectiveness, and the importance of risk communication and stigma reduction strategies. The review also discusses the role of genomic surveillance, point-of-care diagnostics, and the One Health approach in strengthening future outbreak preparedness and response. Despite substantial progress in understanding mpox since 2022, important uncertainties remain regarding long-term control strategies, equitable access to vaccines and therapeutics, and the management of emerging viral variants. Continued international collaboration, investment in surveillance infrastructure, and improved global health equity will be essential for reducing the impact of future mpox outbreaks.

  • Open Access

    LIPEDEMA AS A DIAGNOSTIC CHALLENGE: A NARRATIVE REVIEW OF CLINICAL PRESENTATION, DIFFERENTIAL DIAGNOSIS AND PSYCHOSOCIAL CONSEQUENCES FOR WOMEN

    by Adrianna Baran, Olaf Krawczyk, Wojciech Kopyciński, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Katarzyna Boszczyk, Małgorzata Grzybowska, Aleksandra Palka

    Lipedema is a chronic, progressive disorder of subcutaneous adipose tissue that predominantly affects women. It is characterised by symmetrical, bilateral and disproportional subdermal fat agglomeration of lower and upper limbs sparing the hands and feet. Main lipedema symptoms are pain, heaviness in the affected areas, easy bruising and hypersensitivity to touch. The diagnosis of lipedema remains challenging. It is often misdiagnosed as obesity or lipedema due to lack of knowledge about this condition, and absence of standardized diagnostic criteria. Apart from clinical manifestation it is crucial to highlight that lipedema significantly affects patients quality of life. Patients emphasize that lipedema affects their daily functioning, causes mobility problems, and impacts their relationships with others. They often face stigmatizing comments about their body shape and are frequently told that they are lazy and should lose weight, despite the fact that weight loss does not reduce excess adipose tissue in the affected areas. Furthermore, lipedema is associated with an increased risk of depression, anxiety, and eating disorders. Therefore, increasing awareness of the disease, distinguishing it from obesity and lymphedema, and enabling timely diagnosis and treatment are essential to improve patients’ quality of life and daily functioning.

  • Open Access

    THE INFLUENCE OF DIET ON THE COURSE OF PSORIASIS WITH PARTICULAR EMPHASIS ON THE MEDITERRANEAN DIET: A LITERATURE REVIEW

    by Natalia Krzysztofek, Olaf Krawczyk, Piotr Wilczkowski, Wojciech Kopyciński, Norbert Krawczyk, Monika Kamela, Małgorzata Grzybowska, Katarzyna Boszczyk, Adrianna Baran, Aleksandra Palka

    Psoriasis is a chronic, immune-mediated inflammatory disease increasingly recognised as a systemic disorder linked to obesity, metabolic syndrome, and cardiovascular comorbidity. Because these comorbidities share an inflammatory and metabolic substrate that is sensitive to nutritional status, diet has attracted growing interest as a modifiable factor capable of shaping the clinical course of the disease. The objective of this review was to synthesise the current evidence on the relationship between dietary patterns, individual nutrients, and the severity of psoriasis, with particular attention to the Mediterranean diet as an integrated anti-inflammatory model. A review of the medical literature was conducted by searching the main biomedical databases and screening reference lists. The evidence indicates that overweight and obesity are consistently associated with greater disease severity and a poorer response to systemic and biologic therapies, whereas a low-calorie diet and weight loss reduce disease activity. Long-chain omega-3 fatty acids, dietary antioxidants, and polyphenol-rich foods have clear anti-inflammatory effects, while a gluten-free diet appears beneficial in patients with serological markers of gluten sensitivity. Higher adherence to the Mediterranean diet is repeatedly reported to be inversely associated with disease severity and with markers of systemic inflammation. Collectively, the evidence supports dietary modification, and a Mediterranean pattern in particular, as a rational and low-risk adjunct to standard pharmacological management, although the predominance of observational data underscores the need for adequately powered, prospective interventional trials.

  • Open Access

    PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF SYSTEMIC SCLEROSIS – AN INTEGRATIVE REVIEW OF THE CURRENT APPROACHES

    by Olaf Krawczyk, Wojciech Kopyciński, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Katarzyna Boszczyk, Małgorzata Grzybowska, Adrianna Baran, Aleksandra Palka

    Systemic sclerosis is a rare autoimmune connective tissue disorder marked by immunological dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs, resulting in considerable morbidity and mortality. The disease results from a complex interaction between genetic susceptibility, epigenetic modifications, environmental triggers, endothelial dysfunction, and aberrant immune responses. These mechanisms promote persistent inflammation, stimulation of fibroblasts and abundant extracellular matrix deposition, eventually causing irreversible tissue fibrosis and organ dysfunction. The diagnosis is based on clinical manifestations, supported by specific antibodies detection, capillaroscopy, and appropriate functional and imaging tests. To facilitate diagnosis, the American College of Rheumatology/European League Against Rheumatism issued guidelines in 2013, enabling earlier diagnosis and more accurate prognostic assessment. Although no curative therapy is currently available, treatment has advanced considerably and focuses on suppressing disease activity, slowing fibrosis, and preventing organ complications. Current therapeutic strategies include immunosuppressive agents, biologic therapies, antifibrotic drugs, and targeted vasodilator treatments tailored to individual organ involvement. Emerging approaches, such as JAK-STAT pathway inhibitors, CAR-T cell therapy, and stem cell transplantation, may further improve long-term outcomes in selected patients. Despite substantial progress in understanding disease mechanisms and expanding therapeutic options, systemic sclerosis remains a clinically heterogeneous disorder requiring early diagnosis, multidisciplinary management, and individualized treatment to optimize survival and quality of life.